Predictive Value of MRI for Clinical Outcomes - European Medical Journal
×

Browse

Predictive Value of MRI for Clinical Outcomes

| Download as | PDF
Chairpeople:
Massimo Filippi1
Speakers:
Maria Pia Sormani,2 Andrew Chan,3 Hans-Peter Hartung4
Disclosure:

Professor Massimo Filippi serves on the scientific advisory boards for Teva and Biogen Idec; has received compensation for consulting services and/or speaking activities from Bayer Schering Pharma, Biogen Idec, Merck Serono, Sanofi-Aventis, and Teva Pharmaceutical Industries; and has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s Drug Discovery Foundation (ADDF), and the Jacques and Gloria Gossweiler Foundation (Switzerland). Professor Maria Pia Sormani has received honoraria and speakers’ fees from Novartis, Biogen Idec, Genzyme (a  Sanofi company), Roche, and Merck Serono. Professor Andrew Chan has received speakers’ honoraria,  contributed to advisory boards, or received research support from Almirall, Biogen Idec, Bayer Schering, Genzyme, Merck Serono, Novartis Pharma, Teva Pharmaceutical Industries, and Sanofi. Professor HansPeter Hartung declares the receipt of honoraria and consultation fees from Biogen Idec GmbH, GeNeuro, Opexa Therapeutics, Merck Serono, Teva, Genzyme (a Sanofi company), MedImmune, Hoffmann-LaRoche, Novartis, and Bayer.

Acknowledgements:

Writing assistance was provided by Dr Nicola Ray, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Genzyme. The views and opinions expressed are those of the authors.

Citation
EMJ Neurol. ;3(Suppl 2):2-7.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as  surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and  informative. The mechanisms of action of teriflunomide (Aubagio®) and alemtuzumab (Lemtrada®), both treatments for relapsing-remitting MS, were discussed, and their Phase II and III safety and efficacy data were reviewed alongside the MRI-derived outcome measures.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.